Ajay Major, Assistant Professor of Medicine at the University of Colorado School of Medicine, shared a post on X:
“MALIBU R + ibrutinib in 1L adv-stage ENZML
126 pts, all int/high MALT-IPI risk
BOR 62%, 3-yr PFS 72%, OS 93%
15% Gr3+ afib
Max 2 yrs of ibrutinib, but relatively toxic. 2nd gen BTKi better?”
More posts featuring Ajay Major.
